Previous studies have suggested that the activation of B-cells could contribute to systemic complications in pSS [14]–[19] but they were retrospective or cross-sectional, concerned one isolated serum marker (beta2-microglobulin [18] or BAFF [19] for example), past or current systemic complications, without concomitant assessment of disease activity and serum markers. The gene discussed is TNFSF13B; the disease is peeling skin syndrome.